索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]黄至齐 陈牧雷.心房颤动合并急性冠脉综合征抗栓治疗的进展[J].国际心血管病杂志,2018,05:266-269.
点击复制

心房颤动合并急性冠脉综合征抗栓治疗的进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2018年05期
页码:
266-269
栏目:
综述
出版日期:
2019-02-01

文章信息/Info

Title:
-
作者:
黄至齐 陈牧雷
Author(s):
-
关键词:
心房颤动;  急性冠脉综合征;  抗栓治疗;  口服抗凝药
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2018.05.003
文献标识码:
-
摘要:
急性冠脉综合征(ACS)和心房颤动都是临床常见的心血管疾病,目前关于心房颤动合并ACS的联合抗栓治疗尚无最佳方案,临床医师需要根据患者的栓塞及出血风险综合考虑。随着新型口服抗凝药(如达比加群酯、利伐沙班、阿哌沙班、依度沙班)的问世,临床上有了更多的选择。该文介绍心房颤动合并ACS患者抗栓治疗的进展
Abstract:
-

参考文献/References


[1] 周自强, 胡大一, 陈捷, 等. 中国心房颤动现状的流行病学研究[J]. 中华内科杂志, 2004, 43(7):491-494.
[2] Foussas S. Acute coronary syndromes and atrial fibrillation[J]. Hellenic J Cardiol, 2016, 57(2):141-142.
[3] Jabre P, Roger VL, Murad MH, et al. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis[J]. Circulation, 2011, 123(15):1587-1593.
[4] Hersi A, Alhabib KF, Alsheikh-Ali AA, et al. Prognostic significance of prevalent and incident atrial fibrillation among patients hospitalized with acute coronary syndrome: findings from the Gulf RACE-2 Registry[J]. Angiology, 2012, 63(6):466-471.
[5] Mehta RH, Dabbous OH, Granger CB, et al. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation[J]. Am J Cardiol, 2003, 92(9):1031-1036.
[6] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur J Cardiothorac Surg, 2016, 50(5):e1-e88.
[7] 中华医学会心血管病学分会, 中国老年学学会心脑血管病专业委员会, 中国生物医学工程学心律分会, 等. 心房颤动抗凝治疗中国专家共识[J]. 中华内科杂志, 2012, 51(11):916-921.
[8] Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC)[J]. Europace, 2010, 12(10):360-1420.
[9] Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation[J]. Chest, 2010, 137(2):263-272.
[10] Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score(HAS-BLED)to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey[J]. Chest, 2010, 138(5):1093-1100.
[11] Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association[J]. Eur Heart J, 2012, 33(21):2719-2747.
[12] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 抗血小板治疗中国专家共识[J]. 中华心血管病杂志, 2013, 41(3):183-194.
[13] January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J]. Circulation, 2014, 64(21):e1-e76.
[14] 袁勋, 王文尧, 张阔, 等. 冠心病合并心房颤动患者经皮冠状动脉介入治疗术后抗血小板抗凝治疗策略[J]. 中国循环杂志, 2015(8):723-727.
[15] Ho KW, Ivanov J, Freixa X, et al. Antithrombotic therapy after coronary stenting in patients with nonvalvular atrial fibrillation[J]. Canadian Journal of Cardiology, 2013, 29(2):213-218.
[16] Mennuni MG, Halperin JL, Bansilal S, et al. Balancing the risk of bleeding and stroke in patients with atrial fibrillation after percutaneous coronary intervention(from the AVIATOR registry)[J]. Am J Cardiol, 2015, 116(1):37-42.
[17] Rubboli A, Schlitt A, Kiviniemi T, et al. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry[J]. Clin Cardiol, 2014, 37(6):357-364.
[18] Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial[J]. Lancet, 2013, 381(9872):1107-1115.
[19] Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention[J]. J Am Coll Cardiol, 2013, 62(11):981-989.
[10] Fosbol EL, Wang TY, Li S, et al. Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction[J]. Am Heart J, 2012, 163(4):720-728.
[21] Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI[J]. N Engl J Med, 2016, 375(25):2423-2434.
[22] Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation[J]. N Engl J Med, 2017, 377(16):1513-1524.

备注/Memo

备注/Memo:
作者单位:100020 首都医科大学附属北京朝阳医院心脏中心和高血压病研究北京市重点实验室(第一作者现工作于民航总医院空勤干部科)
通信作者:陈牧雷,Email:cml68@sina.cn
更新日期/Last Update: 2018-09-30